SEARCH

SEARCH BY CITATION

References

  • Atra, A., Gerrard, M., Hobson, R., Imeson, J.D., Ashley, S., Pinkerton, C.R. on behalf of the UKCCSG (1998) Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and Stage IV B-cell non-Hodgkin's lymphoma (B-NHL) – results of the UKCCSG 9003 protocol. British Journal of Cancer, 77, 22812228.
  • Atra, A., Imeson, J.D., Hobson, R., Gerrard, M., Hann, I.M., Eden, O.B., Carter, R.L., Pinkerton, C.R. on behalf of the UKCCSG (2000) Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL) – results of the UKCCSG 9002 protocol. British Journal of Cancer, 82, 13961403.
  • Bowman, W.P., Shuster, J.J., Cook, B., Griffin, T., Behm, F., Pullen, J., Link, M., Head, D., Carroll, A., Berard, C., Murphy, S. (1996) Improved survival for children with B-cell acute lymphoblastic leukaemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology study group. Journal of Clinical Oncology, 14, 12521261.
  • Cairo, M., Krailo, M., Morse, M., Hutchinson, R., Harris, R., Kjeldesberg, C., Kadin, M., Redel, E., Steinherz, L., Meadow, A. (1996) Disseminated non-lymphoblastic non-Hodgkin's lymphoma (DNLHL) of childhood: a randomised phase II trial of short intensive treatment (abstract 093). Annals of Oncology, 7, 29.
  • Colombat, P., Biron, P., Patte, C., Harousseau, J.L., Demecq, F., Benz-Lemoine, E., Frappaz, D., Lamagnere, J.P., Philip, T. (1990) High-dose etoposide and cisplatin in refractory or recurrent non-Hodgkin's lymphoma (NHL). Nouvelle-Revue-Francaise-d'Hematologie, 32, 183186.
  • Frappaz, D., Patte, C., Michon, J., Leverger, G., Berhendt, H., Rubie, H., Perel, Y., Bertrand, Y., Gentey, J.C., Thyss, A., Hartmann, O., Philip, T. for the SFOP (1993) 14 relapses out of 225 children from the SFOP non-Hodgkin's B lymphoma LMB-89 (abstract 80). Medical Pediatric Oncology, 21, 551.
  • Gentet, J.C., Patte, C., Quintana, E., Bergeron, C., Rubie, H., Pein, F., Damaille, M.C., Philip, T., Raybaud, C. (1990) Phase II study of cytarabine and etoposide in children with refractory or relapsed non-Hodgkin's lymphoma: a study of the French Society of Pediatric Oncology. Journal of Clinical Oncology, 8, 661665.
  • Grossbard, M.L., Gribben, J.G., Freedman, A.S., Lambert, J.M., Kinsella, J., Rabinowe, S.N., Eliseo, L., Taylor, J.A., Blattler, W.A., Epstein, C.L., Nadler, L.M. (1993) Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood, 81, 22632271.
  • Patte, C., Philip, T., Rodary, C., Zuker, J.M., Behrendt, H., Gentet, J.C., Lamagnere, J.B., Otten, J., Dufillot, D., Pein, F., Caillou, B., Lemerle, J. (1991) High survival rate in advanced stage B cell lymphoma and leukaemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomised trial of 216 children. Journal of Clinical Oncology, 9, 123132.
  • Patte, C., Frappaz, D., Bertrand, Y., Leverger, G., Coze, C., Michon, J., Boutard, P., Babin-Boilletot, A., Baruchel, A., Thyss, A., De Lumley, L. on behalf of the SFOP (1999) Outcome of relapsed childhood B-cell lymphoma (BCL) after intensive first line treatment (Tt): the experience of the French Society of Pediatric Oncology (SFOP) in the LMB89 protocol. (abstract 104). Medical Pediatric Oncology, 33, 218.
  • Philip, T., Hartmann, O., Pinkerton, C.R., Zuker, J.M., Gentet, J.C., Lamagnere, J.P., Berhendt, H., Perel, Y., Otten, J., Lutz, P., Rodary, C., Caillou, B., Bayle, C., Chauvin, F., Patte, C. (1993) Curability of relapsed childhood B-cell non-Hodgkin's lymphoma after intensive first line therapy: a report from the Societe Francaise de Oncologie Pediatrique. Blood, 81, 20032006.
  • Reiter, A., Schrappe, M., Parwaresch, R., Henze, G., Muller-Weihrich, S., Sauter, S., Sykora, K.W., Ludwig, W.D., Gander, H., Riehm, H. (1995) Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified from biological subtypes and stage – a report of the Berlin–Frankfurt–Munster Group. Journal of Clinical Oncology, 13, 359372.